FDA clears Caliway's trial of CBL-514 for localised fat reduction

3 pointsposted a month ago
by daoboy

1 Comments

daoboy

a month ago

This is different than the glps, directly targeting subcutaneous fat.

Link to an earlier paper on the treatment: https://pmc.ncbi.nlm.nih.gov/articles/PMC9384315/ "At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics."